Definium Reports Q2 2026 Results: $1.1B Cash, Voyage GAD Data Next Week

summarizeSummary

Definium Therapeutics reported Q2 2026 financials with $1.1 billion in cash and a $159 million net loss driven by non-cash warrant accounting. The Phase 3 Voyage study in GAD reads out next week, with Panorama to follow in September — near-term catalysts that could significantly move the stock.

check_boxKey Events · Earnings and Guidance · DFTX

• Q2 2026 Net Loss of $159M

  Net loss widened to $159.0M from $42.7M a year ago, largely due to an $86.2M non-cash increase in warrant liability fair value driven by the share price rise. R&D expenses grew to $48.7M, G&A to $26.4M.

• $1.1B Cash Runway into 2030

  Cash, equivalents, and investments totaled ~$1.1B as of June 30, 2026, following the $805M public offering. Management expects this funds operations into 2030, covering all planned clinical milestones.

• Voyage GAD Data Imminent

  Topline results from the Phase 3 Voyage study in generalized anxiety disorder are expected the week of August 10, 2026 — just days away. The study enrolled 214 participants testing DT120 ODT 100 µg vs placebo.

• Panorama GAD Data in September

  The second Phase 3 GAD study, Panorama, with 245 participants, is on track for topline data in September 2026. Together with Voyage, these results will define the GAD opportunity.

auto_awesomeAnalysis · DFTX · Life Sciences

Definium Therapeutics posted a $159 million net loss for Q2 2026, heavily impacted by an $86.2 million non-cash warrant liability remeasurement tied to its rising share price — not a cash outflow or new dilution. The real story is the $1.1 billion cash position, which funds operations into 2030, and the imminent Phase 3 Voyage readout in generalized anxiety disorder expected the week of August 10. With Voyage data just days away and Panorama results in September, the company is at a critical catalyst inflection point that could define the commercial opportunity for DT120 ODT.